Our personalized programs are designed to help you lose weight sustainably, manage cravings, and make food choices that nourish both body and mind
Of course, Ill have to insert some balance in the future, or Ill, you know, die
The inclusion of glucagon agonism is why retatrutide produces such dramatically different outcomes in liver fat reduction compared to GLP-1 only compounds
This pathway is also relevant for Medicare Part D: the Treat and Reduce Obesity Act, signed into law in late 2025, requires Part D plans to cover at least one FDA-approved anti-obesity medication effective April 2026, and Wegovy's CV indication may offer an even earlier coverage pathway for beneficiaries with established heart disease
Improved Glycemic Control and Energy Patients using Retatrutide often experience improved glycemic control, meaning more stable blood sugar levels throughout the day
NT-pro-BNP and TMAO levels were moderately but significantly correlated ( r = 0.524, p = 0.010)